RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis
Video navigation menu
Class 1A guideline recommendations are not followed well in clinical practice 0:29
What are the consequences if HF patients are not on optimal therapy? 3:25
Hyperkalemia is an inherent risk of RAAS inhibiting treatment, but does not elimate its benefit 6:19
Hyperkalemia can be prevented if monitoring frequently as per recommendations. 9:32
How may the new potassium binders be of benefit to optimise RAAS inhibitory therapy? 11:10
Summary 13:17
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: